COLORADO SPRINGS, Colo.,
Nov. 13, 2014 /PRNewswire/ --
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in
cannabis formulation-based drug development and related consulting,
is pleased to announce it is moving into 2nd stage
cannabinoid production in Spain.
"These events are sparking a much higher demand from the general
public regarding access to medical cannabis and information
regarding how it can be used to treat various illnesses and
disease," said Raymond C. Dabney,
President, CEO, Co-Founder and Director of the company. "We are
investigating other significant target cannabinoids for increased
production."
He said the company is also on track to deliver extensive data
on CBD and THC levels, along with treatment regimes for many of its
targeted ailments.
"Our year-round growing capabilities give us the ability to meet
the growing demand based on the number of delivery methods we are
developing for various critical ailments," said Mario S. Lap,
Director and President of European Operations. "We will be
providing our formulation and developing scalability and
portability for our pre-clinical programs that will target GMP
production requirements. We're also setting up other patient groups
in Spain and other countries to
use formulations we developed."
The company's cannabinoid winter production crop is expected to
handle its current demand of medications for several targeted
ailments. The company is performing 2nd phase experiments and
preparing the post-experiment production grow to start early
2015.
The previous testing of the harvested cannabis, which included
EU-certified crops as well as the company's own unique strains,
produced end results indicating that its whole extracts produced
unique identifiers that require multiple authentications based on
their significant nature.
"The progress is very exciting thus far," said Dabney. "The data
we've received is critical and enables us to focus on successful
intensive research and conduct laboratory tests of the active
constituents for regiment production. The company believes the
potential medicinal applications using cannabis have shown positive
treatments results for many targeted ailments."
About Cannabis Science, Inc.
Cannabis Science, Inc.,
takes advantage of its unique understanding of metabolic processes
to provide novel treatment approaches to a number of illnesses for
which current treatments and understanding remain unsatisfactory.
Cannabinoids have an extensive history dating back thousands of
years, and currently, there are a growing number of peer-reviewed
scientific publications that document the underlying biochemical
pathways that cannabinoids modulate. The Company works with leading
experts in drug development, medicinal characterization, and
clinical research to develop, produce, and commercialize novel
therapeutic approaches for the treatment for illnesses caused by
infections as well as for age-related illness. Our initial focus is
on skin cancers and neurological conditions.
Forward-Looking Statements
This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing words such as "anticipate," "seek,"
intend," "believe," "estimate," "expect," "project," "plan," or
similar phrases may be deemed "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Some or all of the events or results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and
global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development
of cannabis-based drugs. Cannabis Science, Inc., does not undertake
any duty nor does it intend to update the results of these
forward-looking statements.
Cannabis Science, Inc.
Mr. Mario S. Lap, Director,
President of European Operations
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Cannabis Science, Inc.
Raymond C. Dabney, Management
Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.